申请人:DALIAN UNIVERSITY OF TECHNOLOGY
公开号:US20210030873A1
公开(公告)日:2021-02-04
A photosensitizer and derivative, application thereof. The photosensitizer has the structure of general formula I, wherein X is S or Se, Y is organic or inorganic ion, R
1
and R
2
are independently selected from H, alkyl, alkoxy, alkyl amido, alkyl azide and the like; R
3
is selected from H, alkyl, alkoxy, amino sulfonyl, hydroxyl, carboxyl and the like, and L
1
is a linker selected from —(CH
2
)
n1
— or —(CH
2
CH
2
O)
n2
—. The derivatives are molecular medicines with drug molecules of anticancer and chemotherapy or tumor targeting function connected to the said photosensitizer. The photosensitizer has excellent near infrared characteristics and low dark toxicity and is used in the field of photodynamic tumor therapy. The introduction of benzophenothiazine or benzophenoselenazine into derivatives with tumor-targeting function could improve the specific uptake of photosensitizer in tumor tissues. Moreover, clinical anticancer drugs can be introduced into the structure of benzophenothiazine or benzophenoselenazine to achieve the purpose of combining therapy of photodynamic therapy and chemotherapy.
一种光敏剂及其衍生物的应用。该光敏剂具有一般式I的结构,其中X为S或Se,Y为有机或无机离子,R1和R2分别选自H、烷基、烷氧基、烷基酰胺基、烷基叠氮基等;R3选自H、烷基、烷氧基、氨基磺酰基、羟基、羧基等,L1为选自—(CH2)n1—或—(CH2CH2O)n2—的连接剂。这些衍生物是具有抗癌和化疗或肿瘤靶向功能的药物分子。该光敏剂具有优异的近红外特性和低暗毒性,用于光动力学肿瘤治疗领域。将苯并噻嗪或苯并硒噻嗪引入具有肿瘤靶向功能的衍生物中,可以提高光敏剂在肿瘤组织中的特异性摄取。此外,临床抗癌药物可以引入苯并噻嗪或苯并硒噻嗪的结构中,以实现光动力疗法和化疗的联合治疗目的。